The Use of Biologics During the COVID-19 Pandemic

During the coronavirus disease 2019 (COVID-19) pandemic, there has been considerable discussion regarding the use of biologics in patients with inflammatory skin conditions, such as psoriasis, hidradenitis suppurativa, and atopic dermatitis. This article discusses clinical trial data, real-world evi...

Descripción completa

Detalles Bibliográficos
Autores principales: Jones, Madison E., Kohn, Alison H., Pourali, Sarah P., Rajkumar, Jeffrey R., Gutierrez, Yasmin, Yim, Rebecca M., Armstrong, April W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8166518/
https://www.ncbi.nlm.nih.gov/pubmed/34556244
http://dx.doi.org/10.1016/j.det.2021.05.010
_version_ 1783701520774070272
author Jones, Madison E.
Kohn, Alison H.
Pourali, Sarah P.
Rajkumar, Jeffrey R.
Gutierrez, Yasmin
Yim, Rebecca M.
Armstrong, April W.
author_facet Jones, Madison E.
Kohn, Alison H.
Pourali, Sarah P.
Rajkumar, Jeffrey R.
Gutierrez, Yasmin
Yim, Rebecca M.
Armstrong, April W.
author_sort Jones, Madison E.
collection PubMed
description During the coronavirus disease 2019 (COVID-19) pandemic, there has been considerable discussion regarding the use of biologics in patients with inflammatory skin conditions, such as psoriasis, hidradenitis suppurativa, and atopic dermatitis. This article discusses clinical trial data, real-world evidence, and guidelines and recommendations for biologics that inhibit tumor necrosis factor, interleukin (IL)-12/23, IL-17, IL-23, and IL-4/13 during the COVID-19 pandemic. Across these inflammatory skin conditions, existing data generally suggest that biologics do not seem to increase the risk of COVID-19 infection or worsen COVID-19 outcomes. The impact of biologics on COVID-19 is an area of active exploration.
format Online
Article
Text
id pubmed-8166518
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-81665182021-06-01 The Use of Biologics During the COVID-19 Pandemic Jones, Madison E. Kohn, Alison H. Pourali, Sarah P. Rajkumar, Jeffrey R. Gutierrez, Yasmin Yim, Rebecca M. Armstrong, April W. Dermatol Clin Article During the coronavirus disease 2019 (COVID-19) pandemic, there has been considerable discussion regarding the use of biologics in patients with inflammatory skin conditions, such as psoriasis, hidradenitis suppurativa, and atopic dermatitis. This article discusses clinical trial data, real-world evidence, and guidelines and recommendations for biologics that inhibit tumor necrosis factor, interleukin (IL)-12/23, IL-17, IL-23, and IL-4/13 during the COVID-19 pandemic. Across these inflammatory skin conditions, existing data generally suggest that biologics do not seem to increase the risk of COVID-19 infection or worsen COVID-19 outcomes. The impact of biologics on COVID-19 is an area of active exploration. Elsevier Inc. 2021-10 2021-06-01 /pmc/articles/PMC8166518/ /pubmed/34556244 http://dx.doi.org/10.1016/j.det.2021.05.010 Text en © 2021 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Jones, Madison E.
Kohn, Alison H.
Pourali, Sarah P.
Rajkumar, Jeffrey R.
Gutierrez, Yasmin
Yim, Rebecca M.
Armstrong, April W.
The Use of Biologics During the COVID-19 Pandemic
title The Use of Biologics During the COVID-19 Pandemic
title_full The Use of Biologics During the COVID-19 Pandemic
title_fullStr The Use of Biologics During the COVID-19 Pandemic
title_full_unstemmed The Use of Biologics During the COVID-19 Pandemic
title_short The Use of Biologics During the COVID-19 Pandemic
title_sort use of biologics during the covid-19 pandemic
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8166518/
https://www.ncbi.nlm.nih.gov/pubmed/34556244
http://dx.doi.org/10.1016/j.det.2021.05.010
work_keys_str_mv AT jonesmadisone theuseofbiologicsduringthecovid19pandemic
AT kohnalisonh theuseofbiologicsduringthecovid19pandemic
AT pouralisarahp theuseofbiologicsduringthecovid19pandemic
AT rajkumarjeffreyr theuseofbiologicsduringthecovid19pandemic
AT gutierrezyasmin theuseofbiologicsduringthecovid19pandemic
AT yimrebeccam theuseofbiologicsduringthecovid19pandemic
AT armstrongaprilw theuseofbiologicsduringthecovid19pandemic
AT jonesmadisone useofbiologicsduringthecovid19pandemic
AT kohnalisonh useofbiologicsduringthecovid19pandemic
AT pouralisarahp useofbiologicsduringthecovid19pandemic
AT rajkumarjeffreyr useofbiologicsduringthecovid19pandemic
AT gutierrezyasmin useofbiologicsduringthecovid19pandemic
AT yimrebeccam useofbiologicsduringthecovid19pandemic
AT armstrongaprilw useofbiologicsduringthecovid19pandemic

Ejemplares similares